SCHEMBL23358610

SCHEMBL23358610

CC1(C)CCC(=O)N1CS(=O)(=O)c1ccc(OC/C(=C/F)CN)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ AOC2 O75106 19/20 1.00
▸ MAOB P27338 5/20 0.77
▸ MAOA P21397 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23358612 1.00 AOC2 (1.00) AOC2MAOBMAOA
SCHEMBL23358629 0.87 AOC2 (1.00) AOC2MAOB
SCHEMBL23358627 0.87 AOC2 (1.00) AOC2MAOB
SCHEMBL23370174 0.86 AOC2 (0.82) AOC2MAOBMAOA
SCHEMBL23358464 0.85 AOC2 (1.00) AOC2MAOBMAOA
SCHEMBL23358463 0.85 AOC2 (1.00) AOC2MAOBMAOA
SCHEMBL23358573 0.85 AOC2 (1.00) AOC2MAOBMAOA
SCHEMBL30007362 0.85 AOC2 (1.00) AOC2MAOBMAOA
SCHEMBL23358570 0.85 AOC2 (1.00) AOC2MAOBMAOA
SCHEMBL23358564 0.80 AOC2 (1.00) AOC2MAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11472769-B2 SSAO inhibitors and use thereof ECCOGENE (SHANGHAI) CO., LTD. (CN) 2022-10-18 — — US claimed
US-20250326721-A1 SSAO INHIBITORS AND USE THEREOF ECCOGENE INC (US) 2025-10-23 — — US disclosed
US-11964942-B2 SSAO inhibitors and use thereof ECCOGENE (SHANGHAI) CO., LTD. (CN) 2024-04-23 — — US disclosed
US-20230026801-A1 SSAO INHIBITORS AND USE THEREOF ECCOGENE INC. 2023-01-26 — — US disclosed
US-20230026801-A1 SSAO INHIBITORS AND USE THEREOF ECCOGENE INC. 2023-01-26 — — US disclosed
US-11472769-B2 SSAO inhibitors and use thereof ECCOGENE (SHANGHAI) CO., LTD. (CN) 2022-10-18 — — US disclosed
US-20210147360-A1 SSAO INHIBITORS AND USE THEREOF ECCOGENE INC. 2021-05-20 — — US disclosed
US-20210147360-A1 SSAO INHIBITORS AND USE THEREOF ECCOGENE INC. 2021-05-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11964942-B2 SSAO inhibitors and use thereof SSB, HAO1, SORD AOC2 39/4885MAOB 21/4885MAOA 17/4885
US-20250326721-A1 SSAO INHIBITORS AND USE THEREOF SSB, HAO1, SORD AOC2 39/4885MAOB 21/4885MAOA 17/4885
US-20230026801-A1 SSAO INHIBITORS AND USE THEREOF SSB, HAO1, SORD AOC2 39/4885MAOB 21/4885MAOA 17/4885
US-11472769-B2 SSAO inhibitors and use thereof SSB, HAO1, SORD AOC2 39/4885MAOB 21/4885MAOA 17/4885
US-20210147360-A1 SSAO INHIBITORS AND USE THEREOF SSB, HAO1, SORD AOC2 39/4885MAOB 21/4885MAOA 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback